Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A new approach to prognosis looks to patients’ genomes for clues about how their cancer will behave.
Genomic tumor profiling in pediatric patients can clarify diagnosis and treatment, a recent study found.
In a small trial, Jemperli led to complete remission in people with a biomarker for deficient DNA repair.
Pediatric patients were matched to therapies targeting specific mutations found in their cancers.
Study confirms that Black men are at higher risk for prostate cancer disease progression and death.
A look back at some of the most important science and treatment news Cancer Health covered this year.
Next-generation genomic testing improved the effectiveness of targeted therapies for certain patients with metastatic breast cancer.
Targeted therapies are available for eight tumor mutations, highlighting the importance of genomic testing.
National Cancer Institute study describes three molecular subtypes of lung cancer in people who have never smoked.
The response rate was nearly 50% for people with breast, colon, pancreatic and other cancers.
More contagious variants add to the struggle agencies already face to trace contacts, communicate with the public and vaccinate residents.
More than 80% of lung cancer patients treated with the targeted therapy experienced remission or had stable disease.
Precision techniques are becoming more broadly applied for men with advanced prostate cancer.
Tagrisso (osimertinib) was approved for non-small cell lung cancer patients with EGFR-positive tumors.
The ways people respond to cancer can sometimes be complex, and often, awesome.
The FoundationOne CDx test identifies solid tumors with NTRK fusions.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.